摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-((二甲基氨基)甲基)哌啶-1-羧酸叔丁酯 | 138022-01-2

中文名称
4-((二甲基氨基)甲基)哌啶-1-羧酸叔丁酯
中文别名
——
英文名称
4-((dimethylamino)methyl)piperidine-1-carboxylic acid tert-butyl ester
英文别名
Tert-butyl 4-((dimethylamino)methyl)piperidine-1-carboxylate;tert-butyl 4-[(dimethylamino)methyl]piperidine-1-carboxylate
4-((二甲基氨基)甲基)哌啶-1-羧酸叔丁酯化学式
CAS
138022-01-2
化学式
C13H26N2O2
mdl
——
分子量
242.362
InChiKey
SRFKYSQSLHKPOK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    304.6±15.0 °C(Predicted)
  • 密度:
    0.985±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.9
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.92
  • 拓扑面积:
    32.8
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency
    摘要:
    in order to obtain more potent growth hormone secretagogues, a comparison of ipamorelin and NN703 suggested the addition of a polar group at the C-terminus of NN703. A study was conducted using constrained amines for this purpose. Here, substituted 4-piperidinylamino- and 4-dimethylaminopiperidino-substitutents were found to give the most active compounds. A replacement of the 4-dimethylaminopiperidino-substituent with 4-hydroxypiperidino resulted in a series of compounds, which showed in vitro activity with EC50 values in the low nanomolar range, and favourable kinetic properties, such as 40% oral bioavailability. The most promising compound was also tested in a swine in vivo model, resulting in a growth hormone level with a C-max of over 40 ng mL(-1). (C) 2002 Editions scientifiques et medicales Elsevier SAS. All rights reserved..
    DOI:
    10.1016/s0223-5234(02)01370-3
  • 作为产物:
    参考文献:
    名称:
    The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency
    摘要:
    in order to obtain more potent growth hormone secretagogues, a comparison of ipamorelin and NN703 suggested the addition of a polar group at the C-terminus of NN703. A study was conducted using constrained amines for this purpose. Here, substituted 4-piperidinylamino- and 4-dimethylaminopiperidino-substitutents were found to give the most active compounds. A replacement of the 4-dimethylaminopiperidino-substituent with 4-hydroxypiperidino resulted in a series of compounds, which showed in vitro activity with EC50 values in the low nanomolar range, and favourable kinetic properties, such as 40% oral bioavailability. The most promising compound was also tested in a swine in vivo model, resulting in a growth hormone level with a C-max of over 40 ng mL(-1). (C) 2002 Editions scientifiques et medicales Elsevier SAS. All rights reserved..
    DOI:
    10.1016/s0223-5234(02)01370-3
点击查看最新优质反应信息

文献信息

  • Compounds with growth hormone releasing properties
    申请人:Peschke Bernd
    公开号:US06919315B1
    公开(公告)日:2005-07-19
    Disclosed are compounds of formula I formula I wherein R 1 , R 2 , R 5 , R 6 , R 7 , R 8 , G, J, L, M, a, b, c, d, e, and f are as defined in the specification, and compositions containing them. These compounds are useful for treating medical disorders resulting from a deficiency in growth hormone.
    揭示了具有公式I的化合物,其中R1、R2、R5、R6、R7、R8、G、J、L、M、a、b、c、d、e和f如规范中定义,并含有它们的组合物。这些化合物可用于治疗由生长激素缺乏引起的医学疾病。
  • [EN] COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES<br/>[FR] COMPOSES A PROPRIETES DE LIBERATION DE L'HORMONE DE CROISSANCE
    申请人:NOVO NORDISK AS
    公开号:WO2000001726A1
    公开(公告)日:2000-01-13
    The invention relates to novel compounds, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone.
    该发明涉及新型化合物、含有它们的组合物以及它们用于治疗由生长激素缺乏引起的医疗障碍的用途。
  • Heterocyclic amides with alpha-4 integrin antagonist activity
    申请人:Carceller Gonzalez Elena
    公开号:US20050143391A1
    公开(公告)日:2005-06-30
    The present invention relates to new compounds of Formula (I) and the salts, solvates and prodrugs thereof, wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as integrin α 4 antagonists.
    本发明涉及公式(I)的新化合物及其盐,溶剂化合物和前药,其中各取代基的含义如说明书所述。这些化合物可用作整合素α4拮抗剂。
  • Orally active renin inhibitors
    申请人:PFIZER INC.
    公开号:EP0661292A1
    公开(公告)日:1995-07-05
    This invention relates to compounds of the formula wherein Z, D, E, R³, R⁴, R⁵ and R⁶ are specified substituents and Q is of the formula: where Y is CH or N, l is O or 1 and R¹ and R² are specified substituents. The compounds are useful as antihypertensive agents.
    本发明涉及式如下的化合物 其中 Z、D、E、R³、R⁴、R⁵ 和 R⁶ 为特定取代基,Q 为式 Q: 其中 Y 是 CH 或 N,l 是 O 或 1,R¹ 和 R² 是指定的取代基。 这些化合物可用作降压药。
  • COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES
    申请人:NOVO NORDISK A/S
    公开号:EP1100824A1
    公开(公告)日:2001-05-23
查看更多